SERIZAWA MASAKUNI 芹澤昌邦

… Alternative Names

Researcher Number	00569915
Other IDs
Affiliation (Current)	2020: 静岡県立静岡がんセンター(研究所), その他部局等, 研究員
Affiliation (based on the past Project Information) *help	2019: 静岡県立静岡がんセンター(研究所), その他部局等, 研究員 2017: 静岡県立静岡がんセンター(研究所), その他部局等, 主任研究員 2014 – 2015: 静岡県立静岡がんセンター(研究所), その他部局等, 主任研究員 2014: 静岡県立静岡がんセンター研究所, 新規薬剤開発・評価研究部, 研究員 2013 – 2014: 静岡県立静岡がんセンター(研究所), その他部局等, その他 … More
Review Section/Research Field	Principal Investigator Tumor therapeutics / Respiratory organ internal medicine / Tumor biology / Basic Section 50020:Tumor diagnostics and therapeutics-related Except Principal Investigator Respiratory organ internal medicine
Keywords	Principal Investigator EGFR-TKI / GLUT1 / PET / 治療効果予測マーカー / 肺癌 / mTOR阻害剤 / FDG / mTOR / 肺がん / 個別化医療 … More Except Principal Investigator 遺伝子異常 / バイオバンク / 分子標的治療 / 遺伝子変異 / 肺癌 Less

がんゲノム解析で蓄積する機能未知遺伝子変異の臨床活用にむけた変異機能推定法の構築Principal InvestigatorOngoing
- Principal Investigator
  
  芹澤昌邦
- Project Period (FY)
  2019 – 2021
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 50020:Tumor diagnostics and therapeutics-related
- Research Institution
  Shizuoka Cancer Center Research Institute
Development of metabolic-targeting therapy for overcoming resistance to EGFR-TKIs in non-small cell lung cancer cellsPrincipal Investigator
- Principal Investigator
  
  Serizawa Masakuni
- Project Period (FY)
  2015 – 2017
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Tumor therapeutics
- Research Institution
  Shizuoka Cancer Center Research Institute
Investigation of novel molecular mechanisms associated with the metastasis of epidermal growth-factor receptor-tyrosine kinase inhibitor-resistant non-small cell lung cancerPrincipal Investigator
- Principal Investigator
  
  SERIZAWA Masakuni
- Project Period (FY)
  2013 – 2014
- Research Category
  
  Grant-in-Aid for Young Scientists (B)
- Research Field
  
  Tumor therapeutics
  Tumor biology
- Research Institution
  Shizuoka Cancer Center Research Institute
Molecular profiling and biomarker study of thoracic malignancies
- Principal Investigator
  
  YAMAMOTO Nobuyuki
- Project Period (FY)
  2012 – 2014
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Respiratory organ internal medicine
- Research Institution
  Wakayama Medical University
  Shizuoka Cancer Center Research Institute
Investigation of the biological mechanism of GLUT1 to develop it as a novel therapeutic predictive biomarker for realization of the personalized lung cancer medicinePrincipal Investigator
- Principal Investigator
  
  SERIZAWA Masakuni
- Project Period (FY)
  2011 – 2012
- Research Category
  
  Grant-in-Aid for Young Scientists (B)
- Research Field
  
  Respiratory organ internal medicine
- Research Institution
  Shizuoka Cancer Center Research Institute

All 2020 2019 2016 2014 2013 2012 2011

All Journal Article Presentation

[Journal Article] Hypoxia Inducible Factor-1α Inhibition in Von Hippel Lindau-mutant Malignant Pleural Mesothelioma Cells.2020
- Author(s)
  Shukuya T, Oyanagi J, Serizawa M, Watanabe M, Yamamoto N, Koh Y.
- Journal Title
  
  Anticancer Res.
  
  Volume: 40 Pages: 1867-1874
- DOI
  10.21873/anticanres.14140
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-19K07792
[Journal Article] Assessment of associations between clinical and immune microenvironmental factors and tumor mutation burden in resected nonsmall cell lung cancer by applying machine learning to whole-slide images2020
- Author(s)
  Ono A, Terada Y, Kawata T, Serizawa M, Isaka M, Kawabata T, Imai T, Mori K, Muramatsu K, Hayashi I, Kenmotsu H, Ohshima K, Urakami K, Nagashima T, Kusuhara M, Akiyama Y, Sugino T, Ohde Y, Yamaguchi K, Takahashi T.
- Journal Title
  
  Cancer Med
  
  Volume: -
- DOI
  10.1002/cam4.3107
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-19K07792, KAKENHI-PROJECT-17K07209
[Journal Article] The Pathologic and Genetic Characteristics of the Intestinal Subtype of Intraductal Papillary Neoplasms of the Bile Duct.2019
- Author(s)
  Nakanuma Y, Kakuda Y, Fukumura Y, Sugino T, Uesaka K, Serizawa M, Terada T, Ohnishi Y.
- Journal Title
  
  Am J Surg Pathol.
  
  Volume: 43 Pages: 1212-1220
- DOI
  10.1097/pas.0000000000001295
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-19K07792
[Journal Article] Characterization of Tumour Mutation Burden in Patients With Non-Small Cell Lung Cancer and Interstitial Lung Disease2019
- Author(s)
  Kobayashi H, Serizawa M, Naito T, Konno H, Kojima H, Mizuno T, Isaka M, Endo M, Nagashima T, Kusuhara M, Urakami K, Ohshima K, Yamaguchi K, Ohde Y, Takahashi T.
- Journal Title
  
  Respirology
  
  Volume: -
- DOI
  10.1111/resp.13726
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-19K07792
[Journal Article] Novel tumor-specific mutations in receptor tyrosine kinase subdomain IX significantly reduce extracellular signal-regulated kinase activity2016
- Author(s)
  Masakuni Serizawa, Masatoshi Kusuhara, Sumiko Ohnami, Takeshi Nagashima, Yuji Shimoda, Keiichi Ohshima, Tohru Mochizuki, Kenichi Urakami, Ken Yamaguchi
- Journal Title
  
  Anticancer Research
  
  Volume: -
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-15K06893
[Journal Article] Peroxisome proliferator-activated receptor γ agonist efatutazone impairs transforming growth factor β2-induced motility of epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer cells2014
- Author(s)
  Sakai K
- Journal Title
  
  Cancer Science
  
  Volume: 104 Pages: 1198-204
- DOI
  10.1111/cas.12411
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23590098, KAKENHI-PROJECT-24501363, KAKENHI-PROJECT-24591186, KAKENHI-PROJECT-25871225
[Journal Article] Identification of metabolic signatures associated with erlotinib resistance of non-small cell lung cancer cells2014
- Author(s)
  Masakuni Serizawa, Masatoshi Kusuhara, Vincent Zangiacomi, Kenichi Urakami, Masaru Watanabe, Toshiaki Takahashi, Ken Yamaguchi, Nobuyuki Yamamoto, Yasuhiro Koh
- Journal Title
  
  Anticancer Research
  
  Volume: 34(6) Pages: 2779-2788
- Peer Reviewed / Acknowledgement Compliant / Open Access
- Data Source
  KAKENHI-PROJECT-25871225
[Journal Article] Assessment of Mutational Profile of Japanese Lung Adenocarcinoma Patients by Multitarget Assays: A Prospective Single-institute Study2014
- Author(s)
  Masakuni Serizawa
- Journal Title
  
  Cancer
  
  Volume: 120 Pages: 1471-1481
- DOI
  10.1002/cncr.28604
- Peer Reviewed / Acknowledgement Compliant
- Data Source
  KAKENHI-PROJECT-24501363, KAKENHI-PROJECT-24591186
[Journal Article] Combined treatment with erlotinib and a transforming growth factor-β type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small cell lung cancer cells2013
- Author(s)
  Masakuni Serizawa
- Journal Title
  
  Journal of Thoracic Oncology
  
  Volume: 8 Pages: 259-69
- DOI
  10.1097/jto.0b013e318279e942
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-24501363, KAKENHI-PROJECT-24591186
[Journal Article] Genomic Aberrations Associated with Erlotinib-resistance in Non-small Cell Lung Cancer Cells2013
- Author(s)
  Masakuni Serizawa, Toshiaki Takahashi, Nobuyuki Yamamoto and Yasuhiro Koh
- Journal Title
  
  Anticancer Research
  
  Volume: 33(12) Pages: 5223-5233
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-25871225
[Journal Article] Combined treatment with erlotinib and transforming growth factor-β type 1 receptor (TGF-βRI) inhibitor is effective to suppress the enhanced cell motility of erlotinib-resistant non-small cell lung cancer cells.2013
- Author(s)
  Serizawa, M., Takahashi, T., Yamamoto, N., Koh, Y.
- Journal Title
  
  J Thorac Oncol.
  
  Volume: 8 Pages: 259-269
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23790928
[Journal Article] Genomic aberrations associated with erlotinib resistance in non-small cell lung cancer cells2013
- Author(s)
  Masakuni Serizawa
- Journal Title
  
  Anticancer Research
  
  Volume: 33 Pages: 5223-33
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-24591186
[Journal Article] The impact of clinical outcomes according to EGFR mutation status in patients with locally advanced lung adenocarcinoma who received concurrent chemoradiotherapy2012
- Author(s)
  Akamatsu, H., Kaira, K., Murakami, H., Serizawa, M., Koh, Y., Ono, A., Shukuya, T., Tsuya, A., Nakamura, Y., Kenmotsu, H., Naito, T., Takahashi, T., Endo, M., Harada, H., Nakajima, T., Yamamoto, N.
- Journal Title
  
  Am J Clin Oncol.
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23790928
[Journal Article] Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma.2012
- Author(s)
  Kaira, K., Serizawa, M., Koh, Y., Takahashi, T., Hanaoka, H., Oriuchi, N., Endo, M., Kondo, H., Nakajima, T., Yamamoto, N.
- Journal Title
  
  Eur J Cancer.
  
  Volume: 48 Pages: 1244-1254
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23790928
[Journal Article] Relationship between (18)F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma2012
- Author(s)
  Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma.
- Journal Title
  
  European Journal of Cancer
  
  Volume: 48 Pages: 1244-1254
- DOI
  10.1016/j.ejca.2012.01.016
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23591750, KAKENHI-PROJECT-23790928
[Journal Article] バイオバンクと個別化医療2011
- Author(s)
  芹澤昌邦、洪泰浩
- Journal Title
  
  Progress in Medicine 基礎・治療
  
  Volume: 31 Pages: 2575-2580
- Data Source
  KAKENHI-PROJECT-23790928
[Journal Article] Expression of excision repair cross-complementation group 1, breast cancer susceptibility 1, and β III-tubulin in thymic epithelial tumors.2011
- Author(s)
  Kaira, K., Serizawa M., Koh, Y., Miura, S., Kaira, R., Abe, M., Nakagawa, K., Ohde, Y., Okumura, T., Naito, T., Murakami, H., Takahashi, T., Kondo, H., Nakajima, T., Endo, M., Yamamoto, N.
- Journal Title
  
  J Thorac Oncol.
  
  Volume: 6 Pages: 606-613
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23790928
[Journal Article] MUC1 expression in thymic epithelial tumors: MUC1 may be useful marker as differential diagnosis between type B3 thymoma and thymic carcinoma.2011
- Author(s)
  Kaira, K., Murakam,I H., Serizawa, M., Koh, Y., Abe, M., Ohde, Y., Takahashi, T., Kondo, H., Nakajima, T., Yamamoto, N.
- Journal Title
  
  Virchows Arch.
  
  Volume: 458 Pages: 615-620
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23790928
[Journal Article] Expression of thymidylate synthase, orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in thymic epithelial tumors.2011
- Author(s)
  Kaira, K, Serizawa, M., Koh, Y., Miura, S., Kaira, R., Abe, M., Nakagawa, K., Ohde, Y., Okumura, T., Murakami, H., Tsuya, A., Nakamura, Y., Naito, T., Takahashi, T., Kondo, H., Nakajima, T., Endo, M., Yamamoto, N.
- Journal Title
  
  Lung Cancer.
  
  Volume: 74 Pages: 419-425
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23790928
[Presentation] オシメルチニブ耐性非小細胞肺癌細胞において活性の変化を示す代謝経路の同定2019
- Author(s)
  梅原里奈、宮脇英里子、釼持広知、大島啓一、浦上研一、解良恭一, 高橋利明、山口建、芹澤昌邦
- Organizer
  第78回　日本癌学会学術総会
- Data Source
  KAKENHI-PROJECT-19K07792
[Presentation] 主要8がん種における日本人と白人のがんゲノム比較解析2019
- Author(s)
  芹澤昌邦、長嶋剛史、川端孝典、盛啓太、釼持広知、杉野隆、丸山宏二、大島啓一、浦上研一、秋山靖人、山口建
- Organizer
  第78回　日本癌学会学術総会
- Data Source
  KAKENHI-PROJECT-19K07792
[Presentation] 遺伝子変異総量は非置換型肺腺癌における独立した予後規定因子である2019
- Author(s)
  井坂光宏、芹澤昌邦、長嶋剛史、児嶋秀晃、今野隼人、水野鉄也、小野哲、大島啓一、秋山靖人、浦上研一、遠藤正浩、杉野隆、山口　建、高橋利明、大出泰久
- Organizer
  第78回　日本癌学会学術総会
- Data Source
  KAKENHI-PROJECT-19K07792
[Presentation] 肺腺癌における個別化医療の推進を目的とした体細胞変異プロファイリング2013
- Author(s)
  芹澤昌邦
- Organizer
  第72回日本癌学会学術総会
- Place of Presentation
  横浜市
- Invited
- Data Source
  KAKENHI-PROJECT-24591186
[Presentation] Implementation of multiplexed mutational profiling into the lung cancer clinic at Shizuoka Cancer Center2012
- Author(s)
  芹澤昌邦
- Organizer
  第71回日本癌学会学術総会
- Place of Presentation
  札幌
- Data Source
  KAKENHI-PROJECT-24591186
[Presentation] Multiplexed mutational profiling in Japanese patients with thoracic malignancies for personalized cancer therapy2012
- Author(s)
  Masakuni Serizawa
- Organizer
  EORTC-NCI-AACR Symposium on 'Molecular Targets and Cancer Therapeutics'
- Place of Presentation
  ダブリン（アイルランド）
- Data Source
  KAKENHI-PROJECT-24591186

1. YAMAMOTO Nobuyuki (60298966)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
2. KOH Yasuhiro (80426519)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
3. KONDO Haruhiko (60399590)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
4. NAKAJIMA Takashi (20124422)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
5. 楠原正俊 (40169991)

# of Collaborated Projects: 1 results

# of Collaborated Products: 1 results
6. 高橋利明 (50507415)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
7. 解良恭一 (40400783)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
8. 石川吉伸 (00305004)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
9. 大島啓一 (10399587)

# of Collaborated Projects: 1 results

# of Collaborated Products: 5 results
10. 釼持広知 (50602637)

# of Collaborated Projects: 1 results

# of Collaborated Products: 2 results
11. 盛啓太 (50727534)

# of Collaborated Projects: 1 results

# of Collaborated Products: 1 results
12. ENDO Masahiro

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
13. 秋山靖人

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results

SERIZAWA MASAKUNI 芹澤 昌邦

芹澤 昌邦 セリザワ マサクニ

Serizawa Masakuni 芹澤 昌邦

SERIZAWA Masakuni 芹澤 昌邦

Research Projects

Research Products

Co-Researchers

がんゲノム解析で蓄積する機能未知遺伝子変異の臨床活用にむけた変異機能推定法の構築Principal InvestigatorOngoing

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Development of metabolic-targeting therapy for overcoming resistance to EGFR-TKIs in non-small cell lung cancer cellsPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Investigation of novel molecular mechanisms associated with the metastasis of epidermal growth-factor receptor-tyrosine kinase inhibitor-resistant non-small cell lung cancerPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Molecular profiling and biomarker study of thoracic malignancies

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Investigation of the biological mechanism of GLUT1 to develop it as a novel therapeutic predictive biomarker for realization of the personalized lung cancer medicinePrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

[Journal Article] Hypoxia Inducible Factor-1α Inhibition in Von Hippel Lindau-mutant Malignant Pleural Mesothelioma Cells.2020

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Assessment of associations between clinical and immune microenvironmental factors and tumor mutation burden in resected nonsmall cell lung cancer by applying machine learning to whole-slide images2020

Author(s)

Journal Title

DOI

Data Source

[Journal Article] The Pathologic and Genetic Characteristics of the Intestinal Subtype of Intraductal Papillary Neoplasms of the Bile Duct.2019

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Characterization of Tumour Mutation Burden in Patients With Non-Small Cell Lung Cancer and Interstitial Lung Disease2019

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Novel tumor-specific mutations in receptor tyrosine kinase subdomain IX significantly reduce extracellular signal-regulated kinase activity2016

Author(s)

Journal Title

Data Source

[Journal Article] Peroxisome proliferator-activated receptor γ agonist efatutazone impairs transforming growth factor β2-induced motility of epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer cells2014

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Identification of metabolic signatures associated with erlotinib resistance of non-small cell lung cancer cells2014

Author(s)

Journal Title

Data Source

[Journal Article] Assessment of Mutational Profile of Japanese Lung Adenocarcinoma Patients by Multitarget Assays: A Prospective Single-institute Study2014

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Combined treatment with erlotinib and a transforming growth factor-β type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small cell lung cancer cells2013

Author(s)

Journal Title

DOI

Data Source

SERIZAWA MASAKUNI 芹澤昌邦

芹澤昌邦セリザワマサクニ

Serizawa Masakuni 芹澤昌邦

SERIZAWA Masakuni 芹澤昌邦